328 related articles for article (PubMed ID: 19853357)
1. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
2. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
3. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
4. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
5. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Oren E; Chegini S; Hamilos DL
Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
[TBL] [Abstract][Full Text] [Related]
6. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
7. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
8. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
9. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
10. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
[TBL] [Abstract][Full Text] [Related]
11. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
12. [The estimation of treatment of Hymenoptera venoms allergy in children].
Botulińska E; Piotrowska T; Korol D; Swiebocka E; Hofman J
Pol Merkur Lekarski; 2006 Sep; 21(123):232-4. PubMed ID: 17163183
[TBL] [Abstract][Full Text] [Related]
13. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
[TBL] [Abstract][Full Text] [Related]
14. Systemic and local reactions of bee venom immunotherapy in Iran.
Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
[TBL] [Abstract][Full Text] [Related]
15. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
White KM; England RW
Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
[TBL] [Abstract][Full Text] [Related]
16. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
17. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
Goldberg A; Confino-Cohen R
Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
[TBL] [Abstract][Full Text] [Related]
19. Hymenoptera venom immunotherapy and field stings.
Lang R; Hawranek T
J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
[TBL] [Abstract][Full Text] [Related]
20. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
